C
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Clyde Bailey is the Director of Bioinformatics at the University of Arkansas for Medical Sciences. His research focuses on understanding and improving outcomes for multiple myeloma, a cancer of plasma cells. He has published on topics including bispecific CAR-T cell therapy, the role of the immune microenvironment in multiple myeloma progression, and the prognostic value of ferritin levels in patients undergoing autologous stem cell transplantation. Bailey has also investigated NEK2 expression in myeloid progenitors and its impact on T-cell immunity, as well as gene signatures that predict the risk of monoclonal gammopathy of undetermined significance (MGUS) progressing to multiple myeloma.
His work involves multi-omics approaches to reveal alterations in the immune microenvironment associated with multiple myeloma and its precursor stages. Bailey also has a significant publication record with key collaborators at the University of Arkansas for Medical Sciences, including John D. Shaughnessy Jr., Guido Tricot, David E. Mery, and Cody Ashby. He has a h-index of 14 with over 1,900 citations across his 94 publications.
Metrics
- h-index: 14
- Publications: 94
- Citations: 1,932
Selected Publications
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)
-
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)
-
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)
-
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)
-
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)
-
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024)
-
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)
-
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)
-
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)
-
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)
-
Global Proteomics Identifies CDK11A/B As Integral to Myeloma Proliferation and High-Risk Disease (2023)
-
Total Therapy (TT)-4: A Phase 3 Trial Comparing L-TT4 and S-TT4 and Tandem Auto Transplants in Standard Risk Multiple Myeloma (2023)
-
A 5-Stage System for ASCT Multiple Myeloma (2023)
-
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023)
Collaboration Network
Top Collaborators
Frits van Rhee
University of Arkansas for Medical Sciences
47 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 47 shared publications
Maurizio Zangari
Winthrop Rockefeller Foundation
33 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 33 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
31 shared publications
In database
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
- Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma
Showing 5 of 31 shared publications
Sharmilan Thanendrarajan
Winthrop Rockefeller Foundation
27 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 27 shared publications
Carolina Schinke
University of Arkansas for Medical Sciences
27 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
Showing 5 of 27 shared publications
Samer Al Hadidi
Winthrop Rockefeller Foundation
25 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
Showing 5 of 25 shared publications
Sarah Waheed
22 shared publications
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 22 shared publications
Nathan Petty
22 shared publications
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 22 shared publications
Joshua Epstein
22 shared publications
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 22 shared publications
Antje Hoering
22 shared publications
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 22 shared publications
John Crowley
22 shared publications
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 22 shared publications
John D. Shaughnessy
University of Arkansas for Medical Sciences
21 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
- Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma
Showing 5 of 21 shared publications
Guido Tricot
University of Arkansas for Medical Sciences
18 shared publications
In database
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- A gene signature can predict risk of MGUS progressing to multiple myeloma
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems
Showing 5 of 18 shared publications
John D. Shaughnessy
Winthrop Rockefeller Foundation (US)
18 shared publications
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages
- Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 18 shared publications
Christoph Heuck
16 shared publications
- Supplementary Table 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 3 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 4 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 1 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
- Supplementary Figure 2 from Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene <i>NR3C1</i>
Showing 5 of 16 shared publications
Similar Researchers
Based on overlapping research topics
Cody Ashby
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Genomics and Phylogenetic Studies
Daisy Alapat
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Immunotherapy and Biomarkers
Immune Cell Function and Interaction
Fritz Van Rhee
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Genomics and Phylogenetic Studies
Cancer-related molecular mechanisms research
Tanvi Patel
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Cancer Immunotherapy and Biomarkers
Bailu Peng
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Cancer Immunotherapy and Biomarkers
David E. Mery
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Genomics and Phylogenetic Studies